Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Tomohiko Shinkawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-6708-5918; OpenAlex author ID A5031927121. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 12

  1. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. Co-author DOI 10.1007/s00432-025-06095-z↗
  2. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  3. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1004↗
  4. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case … Co-author DOI 10.1186/s13256-023-04311-3↗
  5. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  6. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  7. Heterogeneity of Cancer-Associated Fibroblasts and the Tumor Immune Microenvironment in Pancreatic Cancer. Co-author DOI 10.3390/cancers14163994↗
  8. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  9. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Co-author DOI 10.1186/s40792-020-00924-8↗
  10. Correction to: Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Co-author DOI 10.1186/s40792-020-01070-x↗
  11. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  12. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy. First author DOI 10.1007/s00268-018-4496-y↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenoki Ohuchida · 8 shared papers, 2020–2025 · strength 1.30
  2. Masafumi Nakamura · 7 shared papers, 2020–2024 · strength 1.09
  3. Kohei Nakata · 7 shared papers, 2020–2025 · strength 1.04
  4. Naoki Ikenaga · 6 shared papers, 2021–2025 · strength 0.95
  5. Toshiya Abe · 6 shared papers, 2020–2025 · strength 0.92
  6. Chika Iwamoto · 6 shared papers, 2020–2025 · strength 0.84
  7. Noboru Ideno · 4 shared papers, 2022–2025 · strength 0.65
  8. Yoshinao Oda · 4 shared papers, 2022–2024 · strength 0.64
  9. Chikanori Tsutsumi · 4 shared papers, 2020–2025 · strength 0.63
  10. Kazuyoshi Nishihara · 4 shared papers, 2018–2024 · strength 0.59
  11. Toru Nakano · 4 shared papers, 2018–2024 · strength 0.59
  12. Koji Shindo · 4 shared papers, 2020–2024 · strength 0.52
  13. Yuki Mochida · 3 shared papers, 2022–2025 · strength 0.50
  14. Koki Oyama · 2 shared papers, 2024–2025 · strength 0.36
  15. Yusuke Watanabe · 2 shared papers, 2018–2024 · strength 0.33
  16. Kazuhiro Koikawa · 2 shared papers, 2021–2024 · strength 0.26
  17. Shin Kibe · 2 shared papers, 2020–2023 · strength 0.24
  18. Kenjiro Date · 1 shared paper, 2024 · strength 0.23
  19. Yoshinao Oda · 1 shared paper, 2025 · strength 0.21
  20. Masafumi Nakamura · 1 shared paper, 2025 · strength 0.21
  21. Nan Sheng · 1 shared paper, 2024 · strength 0.20
  22. Yohei Ando · 2 shared papers, 2020–2021 · strength 0.19
  23. Akiko Sagara · 2 shared papers, 2020–2021 · strength 0.19
  24. Yoshihiro Miyasaka · 2 shared papers, 2020–2021 · strength 0.19
  25. Takao Ohtsuka · 2 shared papers, 2020–2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.